Clinical trialsCompany release

Lexeo starts pivotal SUNRISE-FA 2 trial of LX2006 in Friedreich ataxia cardiomyopathy

🇺🇸 Lexeo Therapeutics, Inc. (LXEO) · Mon 16 Nov 2026

The US gene therapy developer expects topline data in the second half of 2027 and says a BLA could be filed in the first half of 2028.

Lexeo Therapeutics says its pivotal SUNRISE-FA 2 study of the gene therapy LX2006 in Friedreich ataxia cardiomyopathy began in June 2026. The information comes from the company's corporate presentation, which cites its 10-Q quarterly filing of 12 August 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Lexeo Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Lexeo Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →